LQT Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- LQT Therapeutics's estimated annual revenue is currently $4.2M per year.
- LQT Therapeutics's estimated revenue per employee is $155,000
Employee Data
- LQT Therapeutics has 27 Employees.
- LQT Therapeutics grew their employee count by 0% last year.
LQT Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO, Chairman | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Director Research | Reveal Email/Phone |
4 | Chief Development Officer | Reveal Email/Phone |
LQT Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is LQT Therapeutics?
LQT Therapeutics is a newly established start-up in Laval (Quebec, Canada) which is active in the field of biotechnology research. Our job is to create a drug that will cure Long QT Syndrome (LQTS). It is a genetic disorder that causes an proelongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected ventricular arrhythmias and can be life threatening. -- LQT Therapeutics est une start-up nouvellement installée à Laval (Québec, Canada) qui œuvre dans le domaine de la recherche en biotechnologies. Notre travail consiste à créer un médicament qui permettra de soigner le syndrome du QT long (LQTS). Il s'agit d'une maladie génétique qui provoque une extension entre le début du complexe QRS et la fin des ondes T et Q de l'ECG, indiquant un prolongement de la repolarisation ventriculaire et de la durée du potentiel d'action. L'allongement de ce complexe est associé à des arythmies ventriculaires inattendues et pouvant mettre la vie en danger.
keywords:N/AN/A
Total Funding
27
Number of Employees
$4.2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.6M | 27 | -40% | N/A |
#2 | $4.3M | 28 | 8% | N/A |
#3 | $6.5M | 28 | 8% | N/A |
#4 | $2.8M | 28 | N/A | N/A |
#5 | $3.5M | 29 | 0% | N/A |